ResMed (RMD) Stock Price Target 2026

The average analyst price target for ResMed is $251.76, 5.9% above the current price. Of 15 analysts, 6 rate it Buy, 8 Hold and 1 Sell. Targets range from $180 to $325. The latest change came on Nov 2, 2026, when Canaccord Genuity downgraded ResMed from Buy to Hold.

The Average Analyst Price Target for ResMed is $251.76.

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

6Buy

8Hold

1Sell

Consensus RatingNeutral# Analysts15Avg. Consensus PT$251.76Upside to Avg. PT+5.9%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for ResMed Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 2, 2026	Canaccord Genuity	Shane Storey	Downgrade	Buy→Hold	—
Oct 30, 2026	Citigroup	Laura Sutcliffe	PT Raise	Neutral	$240→$270
Oct 30, 2026	RBC Capital	Craig Wong-Pan	PT Raise	Outperform	$262→$288
Oct 30, 2026	Wells Fargo	Nathan Treybeck	PT Raise	Equal-Weight	$215→$250
Oct 30, 2026	Keybanc	Brett Fishbin	PT Raise	Overweight	$267→$277
Sep 15, 2026	RBC Capital	Craig Wong-Pan	Upgrade	Sector Perform→Outperform	$244→$262
Aug 31, 2026	Keybanc	Brett Fishbin	PT Raise	Overweight	$255→$267
Aug 19, 2026	Rothschild & Co	Jackson Philips	Initiate	Neutral	$230
Aug 7, 2026	RBC Capital	Craig Wong-Pan	PT Raise	Sector Perform	$234→$244
Aug 7, 2026	Piper Sandler	Adam Maeder	PT Cut	Neutral	$233→$225
Aug 7, 2026	Keybanc	Brett Fishbin	PT Cut	Overweight	$260→$255
Aug 7, 2026	Wells Fargo	Nathan Treybeck	PT Cut	Equal-Weight	$225→$215
Jul 15, 2026	Mizuho	Anthony Petrone	PT Cut	Outperform	$235→$220
Jul 13, 2026	Citigroup	Laura Sutcliffe	Downgrade	Buy→Neutral	$270→$235
Jul 10, 2026	Jefferies	Matthew Taylor	PT Cut	Hold	$240→$225
Jul 8, 2026	RBC Capital	Craig Wong-Pan	PT Cut	Outperform	$321→$276
Jul 8, 2026	Wells Fargo	Nathan Treybeck	PT Cut	Equal-Weight	$227→$225
Jun 22, 2026	Keybanc	Justin Patterson	PT Cut	Overweight	$290→$266
Jun 17, 2026	Morgan Stanley	David Bailey	Downgrade	Overweight→Equal-Weight	$286→$230
Jun 15, 2026	Citigroup	Laura Sutcliffe	PT Cut	Buy	$340→$270